UNION CITY, Calif., May 3 Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR) today announced that it will host a conference call and webcast to discuss the results of the FDA Panel meeting on Monday, May 10, 2010 at 4:30 p.m. Eastern / 1:30 p.m. Pacific. Don Bailey, President and Chief Executive Officer; Steve Cartt, Executive Vice President & Chief Business Officer; Dr. David Young, Chief Science Officer; and Dr. Jason Zielonka, Senior Vice President and Chief Medical Officer will participate. The dial-in number for the conference call is 877-941-9205 for domestic participants and 480-629-9835 for international participants.
A taped replay of the conference call will also be available beginning approximately one hour after the call's conclusion and will be available for seven days. This replay can be accessed by dialing 800-406-7325 for domestic callers and 303-590-3030 for international callers, both using passcode 4292117#. To access the live webcast of the call, go to Questcor Pharmaceuticals' website at www.questcor.com. An archived webcast will also be available at www.questcor.com.
Questcor Pharmaceuticals, Inc. is a pharmaceutical company that markets H.P. ActharŪ Gel (repository corticotropin injection). H.P. Acthar Gel ("Acthar") is an injectable drug that is approved for the treatment of certain disorders with an inflammatory component, including the treatment of exacerbations associated with multiple sclerosis ("MS") and to induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that is due to lupus erythamatosus. In addition, Acthar is not indicated for, but is used in treating patients with infantile spasms ("IS"), a rare form of refractory childhood epilepsy, and opsoclonus myoclonus syndrome, a rare autoimmune-related childhood neurological disorder. The Company also markets DoralŪ (quazepam), which is indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. For more information, please visit www.questcor.com.
SOURCE Questcor Pharmaceuticals, Inc.